0001104659-24-063561.txt : 20240520 0001104659-24-063561.hdr.sgml : 20240520 20240520200405 ACCESSION NUMBER: 0001104659-24-063561 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240516 FILED AS OF DATE: 20240520 DATE AS OF CHANGE: 20240520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Astley-Sparke Philip CENTRAL INDEX KEY: 0001376491 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 24966564 MAIL ADDRESS: STREET 1: C/O BIOVEX GROUP, INC. STREET 2: 34 COMMERCE WAY CITY: WOBURN STATE: MA ZIP: 10801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4 1 tm2414961-4_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-05-16 0 0001737953 Replimune Group, Inc. REPL 0001376491 Astley-Sparke Philip C/O REPLIMUNE GROUP, INC. 500 UNICORN PARK DRIVE, SUITE 303 WOBURN MA 01801 1 1 0 0 Executive Chairman 0 Common Stock 2024-05-16 4 S 0 37928 6.47 D 1487350 D Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.55 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. /s/ Shawn Glidden, attorney-in-fact 2024-05-20